Pharma News - Chemdiv

Vividion Therapeutics Announces Strategic Research Collaboration with Celgene Corporation to Discover Therapies Against Transformative, First-in-Class Targets

March 5, 2018, San Diego, CA – Vividion Therapeutics, Inc.

IONIS-HTT Rx (RG6042) Top-Line Data Demonstrate Significant Reductions of Disease-Causing Mutant Huntingtin Protein in People with Huntington's Disease

CARLSBAD, Calif.

$Idera Pharmaceuticals Announces Launch of Global Phase 3 Trial Evaluating IMO-2125 in Combination with Ipilimumab for the Treatment of Anti-PD-1 Refractory Melanoma (ILLUMINATE 301)$

Idera Pharmaceuticals Announces Launch of Global Phase 3 Trial Evaluating IMO-2125 in Combination with Ipilimumab for the Treatment of Anti-PD-1 Refractory Melanoma (ILLUMINATE 301)

EXTON, Pa.

BIAL and WhanIn signed an Exclusive Licensing Agreement for Zebinix in South Korea

February 27th, 2018 - BIAL and WhanIn Pharm.

Big pharma, big data: why drugmakers want your health records

LONDON (Reuters) - Drugmakers are racing to scoop up patient health records and strike deals with technology companies as big data analytics start to unlock a trove of information about how me...

FDA approves Sorrento's non-opioid painkiller patch, shares jump

(Reuters) - Sorrento Therapeutics Inc said on Wednesday the U.

Pfizer could face £502M bill if it comes up short in U.K. patent appeal for Lyrica

The U.

Party drug ketamine could prevent depression and PTSD in women, first study in female rats suggests

Ketamine could help treat stressed-related disorders, such depression and PTSD, in women, new research claims.

Today is Rare Disease Day 2018!

With events happening in over 80 countries and regions across the world, together we can raise awareness to help further the rare disease cause.

Celgene stumbles again, as FDA declines to review multiple sclerosis drug critical to company future

Another embarrassing and costly blunder has befallen Celgene.

Kyowa Kirin and Ultragenyx Announce Crysvita® (burosumab) Receives Conditional Marketing Authorization in Europe for the Treatment of X–Linked Hypophosphatemia in Children

TOKYO and LONDON and NOVATO, Calif.

First medicine to treat neonatal diabetes

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting a marketing authorisation in the European Union (EU) for ...